CRISPR Therapeutics AG (CRSP) vs Iovance Biotherapeutics, Inc. (IOVA)
CRISPR Therapeutics AG and Iovance Biotherapeutics, Inc. are both Biotechnology companies. CRISPR Therapeutics AG is the larger, with a market value of $5.4B against $4.9B — 1.1× the size. Iovance Biotherapeutics, Inc. grew revenue faster over the last twelve months: 34.6% against −64.8%. Iovance Biotherapeutics, Inc. has the higher net margin (−89.1% vs −3,368.7%) and the lower return on invested capital (−43.0% vs 0.00%). Across the 17 metrics below, Iovance Biotherapeutics, Inc. leads on 11 and CRISPR Therapeutics AG on 6.
Valuation
Profitability
| Metric | CRSP | IOVA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 48.40% | 65.16% |
| Operating margin | (3,989.99%) | (92.72%) | 0.00% |
| Net margin | (3,368.72%) | (89.09%) | 0.00% |
| Free cash flow margin | (2,772.74%) | (91.21%) | 0.00% |
| Return on equity | (26.09%) | (40.36%) | (57.72%) |
| Return on assets | (19.28%) | (31.76%) | (49.22%) |
| Return on invested capital | 0.00% | (42.96%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack